New combination pill aims to tackle Tough-to-Treat high blood pressure

NCT ID NCT07700875

Completed Disease control Sponsor: Wuhan Createrna Science and Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a new combination pill, QR12000, can lower blood pressure more effectively than existing medications in people with moderate to severe essential hypertension. Participants are randomly assigned to receive either QR12000, one of its components, or an active control drug. The main goal is to measure the change in sitting systolic blood pressure after 8 weeks of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QR12000 compound tablets
What this could lead to: If successful, QR12000 could offer a new, more effective treatment option for people with moderate to severe high blood pressure.
What could go wrong: This is an early phase 2 trial, so the drug may not prove more effective than existing treatments or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION

Contacts and locations

Show contact details

Locations

Qilu Hospital of Shandong University

Jinan, Shangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.